Recently, Salubris received the Notice of Approval of Clinical Trials approved and issued by National Medical Products Administration, which means tha...
SAL007 is expected to provide a new choice for the treatment of chronic heart failure, and bring new hope to the extensive patients with chronic heart...
Recently, CA Roam Holdings, an affiliated company of Carlyle Asia Phase V Fund under The Carlyle Group, a global investment company, invested USD 260 ...
In August 2020, Salubris received the Notice of Approval of Clinical Trials from National Medical Products Administration, and initiated human clinica...
Salubris Biotherapeutics, Inc., (hereinafter referred to as "SalubrisBio"), as a wholly owned subsidiary of Shenzhen Salubris Pharmaceuticals Co. Ltd....
